tenofovir alafenamide fumarate (TAF)

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), F-star Therapeutics, Inc.

Conditions

HBVHIV InfectionsHepatitis BHepatitis B, Chronic

Phase 2

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

TerminatedNCT04059198

F-star Therapeutics, Inc.HBV, Hepatitis B, Hepatitis B, Chronic

Start: 2019-10-10End: 2020-04-02Updated: 2020-07-21

Unknown Phase

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

CompletedNCT00042289

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2003-06-09End: 2020-09-30Updated: 2025-12-02

Related Papers

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

2021-02-1717 citations

Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum

The Journal of Clinical Pharmacology2018-10-2511 citations

Efavirenz Pharmacokinetics during Pregnancy and Infant Washout

Antiviral Therapy2018-02-0122 citations

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

Frontiers in Pharmacology2016-08-0419 citations

Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women

Clinical Infectious Diseases2015-07-2216 citations

Raltegravir pharmacokinetics during pregnancy.

2014-12-0155 citations

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.

2014-09-257 citations